SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas (BOIL) is experiencing extreme volatility, largely fueled by conflicting weather forecasts and uncertain storage reports. Community sentiment is deeply divided, with traders grappling with predictions of cold snaps versus milder temperatures, all while discussing the impact of natural gas contract rollovers and market dynamics. This creates a challenging environment where sentiment shifts rapidly between bullish and bearish outlooks.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is experiencing significant market attention following promising preliminary Phase 3 trial data, which indicated an 80% reduction in breast cancer recurrence rates. This, coupled with the Board's decision to extend share lock-ups for directors and officers until September 2026, signals strong insider confidence and further fuels discussions among investors. The community is actively debating the stock's low float and high cost to borrow, anticipating a potential short squeeze as long-term holders express conviction in the therapy's market potential.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical ($RARE) is trending following a significant sell-off after its brittle-bone disease drug, setrusumab, failed to meet the primary endpoint in late-stage trials. This unexpected outcome, despite positive secondary data, has sparked intense community debate, with some viewing the dramatic price drop and massive volume as an overreaction and a buying opportunity given the company's other approved products and pipeline. Conversely, others point to fundamental balance sheet concerns and pre-announcement insider selling as justification for the decline.

DigitalBridge Group, Inc. is a global alternative asset manager, which engages in investing in digital infrastructure. The firm focuses on operating businesses across the digital ecosystem, including cell towers, data centers, fiber, small cells, and edge infrastructure. It operates through the following segments: Investment Management, Operating, and Corporate and Other. The Investment Management segment represents the global investment management platform, deploying, and managing capital on behalf of a diverse base of global institutional investors. The Operating segment refers to the digital infrastructure and real estate operating companies, which generally earn rental income from providing use of digital asset space and capacity through leases, services, and other agreements. The Corporate and Other segment includes investment and corporate level activities. The company was founded in 1991 and is headquartered in Boca Raton, FL.

DigitalBridge Group Inc - Ordinary Shares - Class A

DigitalBridge Group (DBRG) is actively trending following news of SoftBank Group's definitive agreement to acquire the digital infrastructure investor for $16 per share in an all-cash deal. While the acquisition price has sparked considerable debate among investors who had anticipated a higher valuation, the move underscores the ongoing strategic importance of data centers and AI infrastructure in the current market.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor (OPEN) is trending amid intense debate surrounding its new CEO's strategic vision, which emphasizes AI integration and a path to profitability by 2026, coupled with recent reports of building momentum in pending home sales. The community is sharply divided, with some investors seeing the current price action as an accumulation opportunity before a potential rebound, while others express deep skepticism about the company's valuation and long-term viability.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending due to its ongoing holiday sweepstakes, which is generating widespread community discussion and mixed reactions. Many users are expressing disappointment over receiving small crypto prizes, such as Solana or Dogecoin, and are complaining about app glitches during the prize reveal. This has led to skepticism and criticism regarding the promotion's value and execution, contrasting with a few users claiming significant wins.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust (SLV) is generating buzz amid significant market volatility, with community discussion centered on a sharp price adjustment attributed by many to increased margin requirements by exchanges and alleged manipulation. Intense debate swirls between those anticipating a major short squeeze driven by robust physical demand and impending Chinese export restrictions, and others cautioning about an overbought market and potential for a substantial correction. The ETF remains a focal point due to silver's critical industrial applications and its role as a perceived safe-haven asset.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is currently a major focus due to upcoming FDA decisions for its promising drug, Relacorilant, with a key PDUFA date for Cushing's syndrome approaching and an NDA recently accepted for platinum-resistant ovarian cancer. The community is actively discussing the potential for significant market expansion and anticipating a substantial short squeeze on positive regulatory outcomes. This strong bullish sentiment is driven by the drug's robust pipeline, which aims to revolutionize treatment across multiple severe conditions.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is generating significant buzz as the community anticipates forthcoming quarterly delivery numbers, with divergent opinions on potential impacts from slowing EV demand. Meanwhile, chatter intensifies around Elon Musk's ambitious year-end robotaxi deadline and recent news of a battery supplier contract reduction, underscoring both the company's bold AI and robotics vision and challenges in its traditional automotive sector.

Starbucks Corp. engages in the production, marketing, and retailing of specialty coffee. It operates through the following segments: North America, International, and Channel Development. The North America segment focuses on the United States and Canada. The International segment is involved in China, Japan, Asia Pacific, Europe, Middle East, Africa, Latin America, and Caribbean. The Channel Development segment includes roasted whole bean and ground coffees, Seattle’s Best Coffee, and Teavana-branded single-serve products. The company was founded by Jerry Baldwin and Howard D. Schultz on November 4, 1985, and is headquartered in Seattle, WA.

Starbucks Corp.

Starbucks Corp

Starbucks is a major talking point following its mixed earnings report, which highlighted the first positive global comparable sales in seven quarters despite an EPS miss. The community is sharply divided between those optimistic about management's turnaround efforts and a recent China stake sale, and others concerned by escalating union strikes, intense competition, and broader consumer spending pressures impacting its high valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Arbutus Biopharma (NASDAQ:ABUS) Share Price Passes Above Two Hundred Day Moving Average - Time to Sell?

Arbutus Biopharma (NASDAQ:ABUS) Shares Cross Above 200-Day Moving Average - What's Next...

Arbutus Biopharma (NASDAQ:ABUS) Stock Price Down 6.4% - What's Next?

Arbutus Biopharma (NASDAQ:ABUS) Trading Down 6.4% - Time to Sell...

Arbutus Biopharma Corporation $ABUS Shares Purchased by Two Seas Capital LP

Two Seas Capital LP increased its holdings in shares of Arbutus Biopharma Corporation (NASDAQ:ABUS - Free Report) by 10.3% during the 2nd quarter, according to its most recent Form 13F filing with...

Arbutus Biopharma (NASDAQ:ABUS) Given Buy Rating at Chardan Capital

Chardan Capital reiterated a "buy" rating and issued a $5.00 price target on shares of Arbutus Biopharma in a research report on Friday...

Arbutus Biopharma (NASDAQ:ABUS) Downgraded by Wall Street Zen to Hold

Wall Street Zen cut Arbutus Biopharma from a "buy" rating to a "hold" rating in a research report on Saturday...

Arbutus Biopharma (NASDAQ:ABUS) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) released its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping analysts' consensus...

Are Medical Stocks Lagging  Arbutus Biopharma (ABUS) This Year?

Here is how Arbutus Biopharma (ABUS) and Boston Scientific (BSX) have performed compared to their sector so far this year.

Is Novartis (NVS) Stock Outpacing Its Medical Peers This Year?

Here is how Novartis (NVS) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.

Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?

Here is how Arbutus Biopharma (ABUS) and Armata Pharmaceuticals, Inc. (ARMP) have performed compared to their sector so far this year.

Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?

Here is how Aquestive Therapeutics (AQST) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

ABUS
Arbutus Biopharma Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ABUS News

ABUSArbutus Biopharma Corp